Arecor Therapeutics plc (AIM:AREC)
London · Delayed Price · Currency is GBP · Price in GBX | Market Cap | 23.60M +43.7% |
| Revenue (ttm) | 1.71M -65.6% |
| Net Income | 664.00K |
| EPS | 0.01 |
| Shares Out | 37.76M |
| PE Ratio | 31.25 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 62.50 |
| Previous Close | 62.50 |
| Day's Range | 62.50 - 62.50 |
| 52-Week Range | 41.00 - 100.00 |
| Beta | -0.21 |
| Analysts | Strong Buy |
| Price Target | 275.50 (+340.8%) |
| Earnings Date | Jun 25, 2026 |
About Arecor Therapeutics
Arecor Therapeutics plc, a clinical stage biotechnology company, develops therapeutics that address diabetes, obesity and other cardiometabolic diseases in the United Kingdom. The company’s lead therapeutic product is the AT278, a disruptor insulin which is designed to transform Automated Insulin Delivery (AID) systems to improve patient care for people living with diabetes. It also develops a novel oral delivery platform using a GLP-1 receptor agonist. Arecor Therapeutics plc was founded in 2007 and is headquartered in Little Chesterford, the ... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 2 analysts, the average rating for AREC stock is "Strong Buy." The 12-month stock price target is 276p, which is an increase of 340.80% from the latest price.
News
Arecor Therapeutics Earnings Call Transcript: H2 2025
Revenue and cash position improved, supported by a $11M non-dilutive financing and reduced expenses. AT278 insulin and oral peptide delivery platforms advance, with phase II trials and key data expected in 2026. Strategic partnerships and a strong cash runway support growth.
Arecor Therapeutics Annual report: H2 2025
Arecor Therapeutics has published its H2 2025 annual report on April 23, 2026.
Arecor Therapeutics Slides: H2 2025
Arecor Therapeutics has posted slides in relation to its H2 2025 quarterly earnings report, which was published on April 23, 2026.
Arecor Therapeutics Annual report: H2 2025
Arecor Therapeutics has published its H2 2025 annual report on April 23, 2026.
Arecor Therapeutics Transcript: Oppenheimer 36th Annual Healthcare MedTech & Services Conference
AT278, an ultra-concentrated, ultra-rapid insulin, targets unmet needs in AID systems, with phase II trials planned and a $3–5 billion U.S. market opportunity. The company is also advancing an oral peptide delivery platform, aiming to improve GLP-1 bioavailability and expand partnerships.
Arecor Therapeutics Slides: Investor presentation
Arecor Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on March 16, 2026.
Half Year 2025 Arecor Therapeutics PLC Earnings Presentation Transcript
Half Year 2025 Arecor Therapeutics PLC Earnings Presentation Transcript
AIM Market Roundup: Wishbone, Nativo Resources, Arecor Therapeutics
Wishbone, Nativo Resources, Arecor Therapeutics, Proteome Sciences and Bradda Head Lithium are today's top movers on London's AIM market
Arecor Therapeutics Earnings Call Transcript: H1 2025
Strong progress on strategic R&D focus, highlighted by a co-development deal for AT278 with Sequel MedTech and a royalty financing agreement with Ligand, extends cash runway into H1 2027. Revenue remains steady, costs are controlled, and key clinical and platform milestones are on track.
Arecor Therapeutics Quarterly report: H1 2025
Arecor Therapeutics has published its H1 2025 quarterly earnings report on September 25, 2025.
Arecor Therapeutics Slides: H1 2025
Arecor Therapeutics has posted slides in relation to its H1 2025 quarterly earnings report, which was published on September 25, 2025.
LGND: Ligand Pharmaceuticals Inks $11M Royalty Deal with Arecor
LGND: Ligand Pharmaceuticals Inks $11M Royalty Deal with Arecor
Arecor extends cash runway with US partnerships
Arecor has bolstered its balance sheet and sharpened its clinical focus, signing two US partnerships that will accelerate its drug pipeline.
AIM Market Roundup: The Revel Collective, Tanfield, Arecor
The Revel Collective, Tanfield, Arecor are today's top risers, while Pantheon Resources, Acuity RM take the biggest fall on London's AIM
Full Year 2024 Arecor Therapeutics PLC Earnings Presentation (Shareholder Q&A) Transcript
Full Year 2024 Arecor Therapeutics PLC Earnings Presentation (Shareholder Q&A) Transcript
Half Year 2024 Arecor Therapeutics PLC Earnings Presentation Transcript
Half Year 2024 Arecor Therapeutics PLC Earnings Presentation Transcript